BioSpace News Archive

MediWound Ltd. announced today that recent clinical data from EscharEx ® Phase II studies will be presented throughout May 2024 at the largest, most prestigious annual meetings in the field of chronic wound care: the European Wound Management Association (EWMA), the Wound Healing Society (WHS), and the Symposium on Advanced Wound Care (SAWC).

Sensus Healthcare, Inc. reminds investors that management will hold a conference call on Thursday, May 9, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2024.

Aquestive Therapeutics, Inc. today announced that it will report results for the first quarter ended March 31, 2024 and provide an update on recent developments in its business after market close on Tuesday, May 7, 2024.

BioStem Technologies Inc. today announced that it will present at the Planet MicroCap Showcase: VEGAS 2024 held at the Paris Hotel & Casino, in Las Vegas, NV., from April 30 - May 2 2024.

Aligos Therapeutics, Inc. wishes to express its condolences on the recent passing of Stephen A. Harrison, MD., Col, FAASLD, who served as a trusted advisor and the Principal Investigator for the Company’s ongoing Phase 2a HERALD study in metabolic dysfunction-associated steatohepatitis subjects.

BioVie Inc. was presented at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit held in Boston, Massachusetts April 23-25.

UNITY Biotechnology, Inc today announced that the Company will present two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held on May 5-9, 2024 in Seattle, Washington.

Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the market.

Standard BioTools Inc. announced that it has initiated a restructuring plan to improve operational efficiency and reduce operating costs, while supporting the execution of the Company’s long-term strategic plan.

Assertio Holdings, Inc., a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that it will release first quarter 2024 financial results on Monday, May 6, 2024, after the market close.